SOURCE: In Veritas Medical Diagnostics, Inc.

November 01, 2006 05:53 ET

In Veritas to Exhibit Several New Applications for Its Technology

INVERNESS, SCOTLAND -- (MARKET WIRE) -- November 1, 2006 -- IVMD (OTCBB: IVME) (FRANKFURT: I7V), a medical device company, is pleased to announce that it will be exhibiting at Medica in Düsseldorf from the 15th to the 18th of November. We will be located on the Scottish Development International stand in Hall 1.

The company will be displaying for the first time examples of its new magnetic particle immunoassay system; its unique low cost, solar powered digital strip reader; and its labour prediction device. The company would be delighted to meet interested parties at the stand and anyone wishing to pre-book an appointment should contact Damian Bond.

Damian Bond, responsible for Business Development at IVMD, says, "Medica is the world's largest exhibition for medical devices and diagnostic products and the perfect meeting place for collaboration partners for IVMD's products. This is the first time that IVMD will show its full capabilities to such a large selection of international companies. The magnetic particle immunoassay in particular is at the cutting edge of technical developments in the point-of-care field and we anticipate considerable interest. The new digital strip reader will also be of significant interest since it has use in a wide variety of applications."

About IVMD, Inc.

IVMD uses its proven, patented core technology to design, develop and test medical devices for near patient testing and monitoring.

Our products serve large global markets in the monitoring of chronic conditions affecting large numbers of the population.

Our first product to market will be a device for measuring the coagulation of blood in patients with cardiovascular disorders. This product is close to market release.

Our scientists are currently working on several other distinct hand-held or highly portable products which make use of our core know-how and technology and are focused on (a) the measurement and detection of pregnancy and labour and (b) the detection of diseases and medical conditions using magnetic detection techniques applied to tissue and blood.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "believe,'' "expects,'' "projects,'' "forecasts,'' "intends,'' "will,'' "anticipated,'' "could,'' or "may,'' and similar conditional expressions are intended to identify forward-looking statements within the meaning of the act and are subject to the safe harbour created by the act. Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties.

Contact Information